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Abstract: Background: The purpose of this study was to describe early changes in the morphol-
ogy of pigment epithelium detachments (PED) after an intravitreal injection of Brolucizumab into
eyes with macular neovascularization secondary to exudative age-related macular degeneration
(e-AMD). Method: We included twelve eyes of 12 patients with PED secondary to e-AMD which
were not responding to prior anti-VEGF treatments. An ophthalmic examination and an assessment
of PED-horizontal maximal diameter (PED-HMD), PED-maximum high (PED-MH) and macular
neovascularization (MNV) flow area (MNV-FA) by the means of structural optical coherence tomog-
raphy (OCT) and OCT Angiography (OCT-A) were performed at baseline, as well as 1, 7, 14 and
30 days after the injection. Results: The mean age of the population of study was 78.4 (SD ± 4.8).
The mean number of previous Ranibizumab or Aflibercept injections was 13 (SD ± 8). At the last
follow-up visit, the PED-HMD did not significantly change (p = 0.16; F(DF:1.94, 20,85) = 1.9), the
PED-MH showed a significant reduction [p = 0.01; F(DF:1.31, 14.13) = 6.84.] and the MNV-FA did not
significantly differ (p = 0.1; F(1.97, 21.67) = 2.54) from baseline. No signs of ocular inflammation were
observed during follow-up. Conclusions: A single Brolucizumab injection was able to determine the
short-term effects on PEDs’ anatomical features of eyes with an unresponsive e-AMD.
Keywords: age-related macular degeneration; innovative biotechnologies; Brolucizumab; exudative
AMD; OCT angiography; personalized medicine
1. Introduction
Worldwide, the incidence and prevalence of age-related macular degeneration (e-
AMD) are relentlessly growing [1,2]. Over the age of 75, the risk of developing early
and late AMD is 25% and 8%, respectively [3]. It was not a long time ago when the
first anti-vascular endothelial growth factor (VEGF) drug received FDA approval for the
treatment of e-AMD, and many steps forward have been made ever since [4]. As the
median age of the general population keeps on growing, the burden associated with the
treatment of AMD is expected to rise consistently. In fact, the overall number of patients
with AMD is predicted to reach 288 million by 2040 [5]. The approval of Pegaptanib
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and previous positive experiences with Bevacizumab in colon cancer management fueled
further research in the field of exudative AMD (e-AMD). In the following years, several
randomized and non-randomized controlled trials have largely demonstrated the efficacy
of different anti-VEGF molecules (i.e., Bevacizumab, Ranibizumab and Aflibercept) at
contrasting macular neovascularization (MNV) [6–8]. Still, some of these trials and other
real-world data made clear that many patients do not fully respond to current treatment
regimens. A post hoc analysis of the VIEW studies showed that around 30% of patients
receiving (q8w) Aflibercept-injections every 8 weeks still display some intra- or subretinal
fluid 52 weeks after the beginning of the treatment [8]. Similarly, other studies showed
that around 25% of the patients treated for e-AMD may be considered as both anatomical
and functional non-responders [9–11]. The need for frequent injections and their high
cost are responsible for a substantial social and economic burden on both patients and
physicians [12].
Recently, a new humanized single-chain variable fragment was developed and named
Brolucizumab (a.k.a. RTH258). By reducing its dimensions compared to the previous
anti-VEGF drugs, this new agent promises to better penetrate the targeted retinal tissues,
to reduce immunogenicity and to provide a longer durability [4]. Particularly, the latter
has been confirmed by two recent randomized clinical trials, where more than half of the
enrolled patients were able to have their neovascularization controlled by a three-monthly
(q12w) treatment regimen [13]. This allows one to decrease the treatment burden and to
improve patients’ compliance [14]. Another important advantage this drug displays is its
high drying effect. Despite the final best corrected visual acuity (BCVA) being similar to
that obtained with q8w. Aflibercept, both after 16 and 48 weeks, Brolucizumab obtained
a significantly lower rate of disease activity (measured by central subfield thickness and
by the presence of intra or subretinal fluid) [12]. Although some severe side-effects have
been reported [15], these seem to be rare and there is evidence supporting the safety of
Brolucizumab [13,16]. Further, the short-term real-world outcomes reported in the SHIFT
study demonstrated that the switch to Brolucizumab may represent a good option in
patients with poorly responsive AMDs [17].
Parallel to the surge of anti-VEGFs and the constant research for other new therapeutic
approaches [18] in the last decade, optical coherence tomography (OCT) has gained a
crucial role in the management of retinal diseases. Indeed, structural OCT allows for an
in vivo analysis of the finest morphological retinal details [19]. Identifying each patients’
disease characteristics is essential in order to define the best patient-tailored treatment
possible. As reported in the pioneering work of Schmidt-Erfurth et al., inter-individual
treatment requirements are vastly heterogeneous, and there is a need to build predictive
models based on automated image analysis of OCT scans in order to address these [19].
Using these models, artificial intelligence (AI) will probably play a major role in future
ophthalmological clinical practice.
The introduction of optical coherence tomography angiography (OCT-A) has recently
fueled the interest in retinal vascular diseases. OCT-A allows for direct visualization of the
retinal and choroidal vascularization without the need for an intravenous dye injection.
Despite having some limitations, this technique grants a fast and sensible detection of any
changes in vessel morphology and overall neovascular-disease activity [20,21]. With the
introduction of Brolucizumab being fairly recent, and the diffusion of OCT-A still not at its
peak, there is a lack of studies analyzing the effects this drug determines on MNV using
the latter technique.
Retinal pigment epithelium detachments (PED), which represent the separation be-
tween the basal lamina of the retinal pigment epithelium (RPE) and the inner collagenous
layers of Bruch’s membrane, are considered to be prominent features of AMD. Three main
types of PED have been described: serous, drusenoid and fibrovascular detachments. The
latter has been classically defined by its angiographic and tomographic appearance, as
characterized by a stippled granular hyperfluorescence and by the presence of a deep area
of backscattering within the PED itself. Additionally, fibrovascular PEDs have always been
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considered to represent a subset of occult choroidal neovascular membranes (CNV) [21].
In recent years, huge steps forward have been made in our understanding of retinal dystro-
phies and of RPE’s role in the development of CNVs [22–25]. However, our knowledge
about the exact pathophysiology of PEDs is still incomplete. This seems to be related to
the accumulation of fluid and debris due to the malfunction of a degenerated Bruch’s
membrane [26].
Since there seems to be a correlation between their morphological structure and their
evolution to exudative AMD, the interest in PEDs’ pathogenesis and their prognostic value
has risen as of late.
To our knowledge, there is currently no study reporting the effects of Brolucizumab
on PEDs associated with a non-responding e-AMD.
By using structural OCT and OCT-A imaging in this study, we aimed to assess the
early changes in pigment epithelium detachment morphology after intravitreal injection of
Brolucizumab into eyes with MNVs.
2. Methods
This study was conducted in agreement with the tenets of the Declaration of Helsinki
for research involving human subjects, and was approved by Institutional Review Com-
mittees (ID number: 3680 approved on 19 January 2021). Written informed consent to
participate in this observational study was obtained from all patients. Inclusion criteria
were (1) a diagnosis of PED secondary to e-AMD, (2) having undergone a Brolucizumab
(Beovu®, Novertis, Basel, Switzerland) injection, (3) the presence of high-quality structural
spectral domain OCT (SD-OCT) and OCT-A images (i.e., signal strength index higher
than 7/10) not affected by artifacts and (4) not being responsive (i.e., absence of any sign
of exudation regression) to other intravitreal anti-VEGFs. Exclusion criteria were the
concomitant presence of ophthalmological diseases potentially able to confound the inter-
pretation of images (e.g., diabetic retinopathy, glaucoma, chorioretinal diseases), the lack
of high-quality images and exudation regression following prior anti-VEGF treatments.
All enrolled patients underwent a comprehensive ophthalmological evaluation. This
included measurement of the BCVA using the early treatment diabetic retinopathy study
(ETDRS) charts and the logarithm of the minimum angle of resolution (LogMAR) system, a
dilated fundus examination and the performance of OCT and OCT-A scans. The latter was
performed using the RTVue XR Avanti OCT-A system (AngioVue system, Optovue® Inc.,
Fremont, CA, USA). Imaging of the retinal lesions and analysis of the lesions’ development
were repeated the day after the injection, and then 7, 14 and 30 days thereafter.
2.1. PED Quantitative Assessment
Both the PED-horizontal maximal diameter (PED-HMD) and the PED-maximum high
(PED-MH) were manually measured using the caliper tool available on all SD-OCT devices.
All measurements were assessed by two independent retinal specialists (M.C.S and
R.K) and compared using the Cohen’s kappa coefficient. The interobserver agreement on
image analysis was 0.92 (k = 0.225, p < 0.01). Examples of PED-HMD and PED-MH are
reported in Figure 1.
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Figure 1. SD-OCT scan of two patients with a PED. The red lines correspond to the PED-HMDs and
the blue lines to the PED-MHs.
2.2. OCT-A and Neovascularization Assessment
MNV flow areas were assessed using a semiautomatic algorithm commercially avail-
able on the OCT-A device. In cases of PEDs with hyporeflective contents not allowing for a
clear visualization of the MNV, we considered the value of the MNV-flow area to be “0”.
An example of MNV-flow area measurement is shown in Figure 2.
Figure 2. MNV-flow area (mm2) defined by the yellow dotted line (Case 1). In Case 2, no flow could
be detected inside the PED; thus, the flow area was considered null.
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2.3. Statistical Analysis
The sample size was calculated via an a priori sample size estimation method using
the G-Power software package (version 3.1.9.6, Universität Kiel, Germany). Assuming a
minimum difference of 15%, a residual standard deviation of 10%, a power of 0.08 and
an alpha of 0.05 to highlight the effect, the required sample size was 12 patients. Data
were analyzed with the GraphPad PRISM Software (v.8.0; GraphPad, La Jolla, CA, USA).
Quantitative variables were presented as mean ± SD and were evaluated using the analysis
of variance (ANOVA) for repeated measures. A pairwise post hoc analysis using Holm–
Sidak’s correction for multiple comparisons test was also performed. A p value less than
0.05 was considered statistically significant.
3. Results
Twelve eyes of 12 patients that did not respond to previous anti-VEGF treatments were
enrolled in the study. Five eyes had previously undergone Ranibizumab or Aflibercept
injections. Seven eyes previously received both Aflibercept and Ranibizumab injections.
Table 1 reports baseline population characteristics.
Table 1. Characteristics of the population of study and details before the Brolucizumab injection.
Mean age, years (SD) 78.4 (±4.8)
gender, n (%) 8/4 (F/M)
Number of previous anti-VEGF injections 13 (±8)(Ranibizumab or Aflibercept)
At baseline, the mean PED-HMD and PED-MH were 1548.36 µm (±1041.96) and
207.36 µm (±82.89), respectively. The mean MNV-flow area was 0.25 mm2 (±0.45) and the
mean BCVA was 0.48 LogMAR (±0.42). MNV-flow area was found to be undetectable on
OCT-A scans of 4 out of 12 eyes (33%).
Details of considered measurements across the different follow-up time points are re-
ported in Table 2. All included eyes (100%) displayed some mixture of intraretinal fluid (IRF)
and subretinal fluid (SRF) concomitant with the PED. None displayed macular hemorrhages.
Table 2. Characteristics of structural OCT and OCT-A at baseline, after 24 h, at 7 days, at 14 days and
1 month after the Brolucizumab injection.






Baseline 1548.36 (±1041.96) 207.36 (±82.89) 0.25 (±0.45) 0.48 (±0.42)
24 h 1588.41 (±897.41) 195.75 (±85.65) 0.22 (±0.41) 0.44 (±0.33)
7 days 1638.72 (±1022.77) 163.25 (±69.53) 0.17 (±0.37) 0.49 (±0.40)
14 days 1398.66 (±959.67) 145.66 (±80.34) 0.12 (±0.34) 0.48 (±0.41)
1 Month 1322.63 (±905.88) 127.5 (±77.79) 0.12 (±0.33) 0.46 (±0.41)
PED: pigment epithelium detachment; PED-HMD: pigment epithelium detachment-horizontal maximal diameter;
PED-MH: pigment epithelium detachment-maximum high; OCTA: optical tomography angiography; MNV-FA:
macular neovascularization-flow area; LogMAR: logarithm of the minimum angle of resolution.
Despite the difference in PED-HMDs between baseline and 1 month after the injection
not being statistically significant [p = 0.16; F (DF: 1.94, 20,85) = 1.9], the PED-MHs showed a
significant reduction during the same follow-up period [p = 0.01; F (DF:1.31, 14.13) = 6.84.]
(Figure 3).
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Figure 3. Box plots showing the significant reduction in PED-MHs from baseline to the end of the
follow-up period. [p = 0.01; F (DF:1.31, 14.13) = 6.84.].
An example of PEDs’ anatomical and functional fluctuation during the follow-up
period is shown in Figure 4.
Figure 4. E-AMD morpho-functional assessment by structural OCT, OCT-A and BCVA. Structural OCT shows the reabsorp-
tion of the subretinal hyper-reflective material (SHRM) and the resolution of the subretinal fluid at the end of the follow-up
period. PED-HMDs did not significantly change during the visits, whereas the PED-MH did. The red and green line show
respectively the vertical and horizontal scan position.
The MNV flow-area failed to show a significant reduction over the observation period
[p = 0.1; F (DF:1.97, 21.67) = 2.54]; although, as previously specified, at baseline, we were
unable to identify any flow area in 4 of the 12 examined eyes.
None of the included eyes displayed a complete disappearance of the MNV after
the injection.
Finally, the BCVA values at the end of the follow-up period were not significantly
different from baseline [p = 0.58; F (2.23, 24.53) = 0.58].
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While the PED-MH showed a continuous reduction during the whole period of
observation, the PED-HMDs displayed an increase at the 7-day timepoint. This, however,
was not statistically significant.
No signs of ocular inflammation (neither in the anterior nor in the posterior segment)
and no other complications were ever observed after the injection of Brolucizumab.
At the end of the follow-up period, all the treated eyes (100%) had their IRF/SRF
completely reabsorbed.
4. Discussion
One of the main goals of medical research is to find diseases’ biomarkers and prog-
nostic factors. This consideration also suits the field of ophthalmology, especially since
multimodal imaging methods have become essential diagnostic tools in everyday clinical
practice [27–29]. Nowadays, OCT and OCT-A play a crucial role in both the diagnosis and
the follow-up of patients with retinal affections. This is particularly true for patients with
both dry and wet AMD [30].
In the former, multimodal imaging is essential for a correct diagnosis and for the
assessment of possible complications (e.g., the simultaneous onset of neovascularization).
The performance of fundus autofluorescence (AF) and enface scans are of particular im-
portance in order to follow patients with atrophic AMDs. In fact, these techniques can
easily identify and help predict any increase in the area of retinal atrophy [31,32]. The
role of an abnormal choriocapillaris perfusion of the macular area also has been recently
reported to be a contributing factor to the progression of non-exudative AMD [33]. The
investigation of retinal pigment epithelial and outer retinal atrophy (RORA) is continuously
developing and can be considered a prognostic factor for atrophy progression or change to
an exudative form of AMD [29,34,35].
Despite the recent technological progress and the improvements in our knowledge of
the disease, interpreting the clinical course of exudative AMD remains challenging. The
search for new diagnostic biomarkers and for signs able to predict the reactivation of the
pathology remains the main goal of retinal clinicians interested in wet AMD. As time goes
on, finding these diseases’ biomarkers through multimodal imaging is crucial in order to
introduce artificial intelligence in the clinical practice [36]. The latter would represent a
huge advantage for both patients and physicians.
The detection of new possible prognostic factors is also important for understanding
the response to our therapies. In vivo histological analysis using OCT scans is probably
the most attractive method for studying the disease through artificial intelligence. In
fact, these scans are rich in details and can be easily accessed by radiomics [37,38]. More-
over, structural OCT and OCT-A are amongst the most effective non-invasive imaging
tools for several retinal diseases. As a matter of fact, in some cases, these techniques are
even considered to be the first-line diagnostic approaches over the older dye imaging
methods [39–41].
PEDs’ morphological features have been previously described to be useful for differ-
entiating and examining some frequently diagnosed clinical entities, such as AMD [42]. In
a recent study by Lupidi et al. [43], the authors reported that PEDs’ SD-OCT-appearance
might be considered as a phenotypic prognostic factor for quiescent MNV. Particularly, they
found the growth in PEDs’ greatest linear diameter to be associated with the maintenance of
a quiescent phenotype, whereas the growth in PEDs’ maximal height was associated more
frequently with the development of an exudative phenotype. The latter was confirmed by
studies by Lam et al. [44] and Serra et al. [43]. These suggest that PEDs’ “contour” mor-
phology might be indicative of a possible future exudative development. Flat, “wrinkled”
PEDs are more prone to quiescence than smooth, peaked ones.
Although previous studies suggest the reduction in the flow area might be consid-
ered a potential biomarker to assess MNV responsiveness to anti-VEGFs, there are some
controversies, since OCT-A has a variable sensitivity [20,45,46].
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As an early response to a single intravitreal Brolucizumab injection in our study, PEDs
showed a significant reduction in their maximal heights [p = 0.01; F = (DF:1.31, 14.13) 6.84.],
whereas no significant difference was found in terms of horizontal maximal diameter, flow
area and BCVA. In the phase 3 Hawk and Harrier trials, 4 weeks after the injection, the
authors showed an increase in BCVA of about four letters [12]. However, these studies
included only naïve patients with a BCVA between 20/32 and 20/400, also excluding those
with macular fibrosis or geographic atrophy. The poor visual acuity results obtained in
our study may be related to both the short-term follow-up and the chronic nature of the
included patients’ disease. The latter may have induced an irreversible degeneration of
the photoreceptors. With regard to the lack of improvement in the MNV-flow area, it has
to be specified that, at baseline, we were able to detect a flow area in only 77% (8/12)
of the included eyes. Despite not being statistically significant, we actually did show a
decrease in the mean flow area (i.e., from 0.25 mm2 (±0.45) at baseline, to 0.12 mm2 (±0.33)
1 month after the injection). The lack of significance might be related to the small number
of study participants. Overall, the literature seems to agree that the injection of anti-VEGFs
usually leads to a reduction in the mean MNV-associated flow area [45,47]. A complete
regression of the MNV after the injection never occurred in our series. In fact, during
follow-up, we were always able to detect a minimum flow on OCT-A scans. This finding
is in agreement with the arterialization sign described by Spaide et al. Despite previous
anti-VEGF treatments, the main trunk of the new vessel is always left behind [48].
One month after the injection, all of the included eyes showed a complete reabsorption
of both the SRF and the IRF they displayed at baseline. This further proves the high drying
effect that Brolucizumab has compared to other anti VEGF agents.
Finally, none of the included patients developed any kind of adverse events. This was
a significant finding, even though we observed our patients for only a limited period of
time. Previously reported incidences of ocular inflammation and retinal artery occlusion
have been as high as 2% and 0.6%, respectively. Such complications might have required a
larger cohort of patients in order to be detected [13].
The lack of detection of low flow rates still represents a major limitation in OCT-A
technology [49]; however, the continuous evolution of new algorithms will soon allow
us to solve this problem. The wide variability in flow-sensibility among different types
of OCT-A devices should be kept in mind when evaluating patients in everyday clinical
practice [50].
Major limitations of our investigation were its limited sample size and its short period
of observation. In the future, we commit to reporting the long-term follow-up outcomes of
this study. Additionally, we did not include any evaluation of the influence Brolucizumab
might have on vitreal proteomic and RPE’s genetic expression. The latter might be an
interesting point to investigate in the future.
Moreover, our results referred to a cohort of patients that had been previously treated
with numerous anti-VEGF injections, and therefore cannot be applied to patients with
naïve e-AMDs.
5. Conclusions
In this study, we demonstrated the significant short-term effects of a single Brolu-
cizumab injection at reducing PEDs’ vertical dimensions in patients with an unresponsive
e-AMD. Further research should be carried out aiming to identify the advantages of the
newest anti-VEGF treatments and the possible biomarkers of e-AMD-responsiveness to
the latter.
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